Enliven Therapeutics Inc. (ELVN) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Enliven Therapeutics Inc. stock $36.16, price $47.62, that is 24.1% below the price, quality 32 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.
Show moreShow less
Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors.
The company was founded in 2019 and is headquartered in Boulder, Colorado.
Stock analysis
Enliven Therapeutics Inc. (ELVN) currently trades at $47.62, while our estimate is $36.16, 24% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $27.12 (bear) to $45.20 (bull), the price of $47.62 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.
Enliven Therapeutics Inc. reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$104M in FY2025.
Key figures
Market cap $3.5B Mid · EPS (TTM) $−1.76 · Return on equity −16.8% · Return on assets (EBIT) −31.3% (5-year average) · Free cash flow −$70.5M · Net cash $150M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).
What moves the price
The share trades about 22% below its 52-week high and 215% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −24%, ELVN screens richer than that median.
Fair Value
Bear$27.12Fair Value $36.16Bull$45.20
Price $47.62 · Downside -24.1%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Quality Score breakdown
Overall quality32/100
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Profitability0
How much profit the company makes from its sales and capital
Quality Growth75
Are margins and returns getting better?
Cashflow12
Do the profits arrive as real cash?
Financial strength92
Debt, balance sheet and risk of trouble
Investment0
Does it invest with discipline instead of growing at any price?
Low Volatility50
How calm the share price moves, does not count
Price momentum62
Price momentum of the last 3 to 12 months, does not count
In the last 6 months, 5 officers or directors sold shares worth $13.9M and none bought.
SaleHelen Louise CollinsCHIEF MEDICAL OFFICER11× since Feb 17, 2026: 165,000 shares, avg. $33.82$5.6MOct 19, 202610b5-1 plan
SaleBenjamin HohlCHIEF FINANCIAL OFFICER6× since Mar 6, 2026: 40,090 shares, avg. $43.98$1.8MOct 19, 2026
SaleJ. Scott GarlandDirector13,000 shares at $46.67$606,719Oct 1, 2026
SaleMika K DerynckDirector158,795 shares at $60.21$9.6MAug 4, 202610b5-1 plan
SaleLori Anne KunkelDirector2× since Jun 5, 2026: 20,000 shares, avg. $42.51$850,226Jul 6, 202610b5-1 plan
SaleORBIMED ADVISORS LLC10% owner2× since Jun 15, 2026: 1,141,531 shares, avg. $45.28$51.7MJun 22, 2026
SaleRichard A. HeymanDirector3× since Jan 8, 2026: 16,380 shares, avg. $25.24$413,427Feb 17, 202610b5-1 plan
SaleJoseph P LyssikatosCHIEF SCIENTIFIC OFFICER5× since Nov 19, 2025: 175,000 shares, avg. $25.82$4.5MFeb 6, 202610b5-1 plan
SaleAnish PatelCHIEF OPERATING OFFICER2× since Dec 8, 2025: 54,963 shares, avg. $27.14$1.5MJan 9, 202610b5-1 plan
SaleSamuel KintzPRESIDENT AND CEO, Director12,500 shares at $21.82$272,750Nov 17, 202510b5-1 plan
Plus 13 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
News mood ⓘNews mood, the average tone of recent news (51 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.
AI conclusion: The narrow moat reflects limited evidence of durable advantage in this pre-revenue biotech, whose main strength is a cash position funding operations well into the next decade while its main weakness remains the absence of any commercial revenue.
Main risk: Failure to navigate the first pivotal trial for relcobatinib in CML would block the sole path to regulatory approval and any future commercial revenue.
Enliven has built a substantial cash reserve that funds operations well into the next decade even as research spending rises. Yet the company still generates no revenue and must successfully navigate its first pivotal trial for relcobatinib in CML. Will the extended runway allow focused execution on the Phase 3 program, or will the lack of near-term income pressure decisions around partnerships or further dilution?
Compare Enliven Therapeutics Inc. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks
Beats the industry median on 1/4 measures
Overall it trails its industry peers.
Valuation
Quality Score32 · Below median
Fair Value upside−24.1% · Above median
Profitability
Return on assets−21.8% · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Enliven Therapeutics Inc. Fair Value". https://www.fairvalue-calculator.com/stock/ELVN
Frequently asked questions
Is Enliven Therapeutics Inc. (ELVN) overvalued or undervalued?
As of Nov 11, 2026, our estimate of fair value is $36.16 versus a price of $47.62, about 24% lower (overvalued).
What is the fair value of ELVN?
Our estimate for Enliven Therapeutics Inc. is $36.16 (as of Nov 11, 2026), built from audited fundamentals. The current price: $47.62.
What is the quality score of ELVN?
Enliven Therapeutics Inc. has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Enliven Therapeutics Inc. (ELVN)?
Our calculated price target is the estimate of $36.16 (as of Nov 11, 2026). Cautious scenario $27.12, optimistic scenario $45.20. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Enliven Therapeutics Inc. stock forecast for 2026?
Our estimate puts fair value at $36.16, about 24% lower versus a price of $47.62 (overvalued). Cautious scenario $27.12, optimistic scenario $45.20. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Enliven Therapeutics Inc. (ELVN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Enliven Therapeutics Inc. it is $36.16 per share (as of Nov 11, 2026), against a price of $47.62.
Is Enliven Therapeutics Inc. stock overvalued or undervalued in 2026?
As of Nov 11, 2026, ELVN trades above its calculated fair value: price $47.62, fair value $36.16, a gap of about −24% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ELVN?
No. The price is what the market pays today ($47.62); the fair value is what the company's own numbers justify ($36.16). For Enliven Therapeutics Inc. the two are $11.46 per share apart. That gap is exactly why we show both numbers side by side.
How much is Enliven Therapeutics Inc. worth?
The market values Enliven Therapeutics Inc. at about $3.5B (market capitalisation, as of Nov 11, 2026). Per share that is $47.62; our models calculate a fair value of $36.16 per share.
What do the bullish and bearish scenarios say about ELVN?
Our models span a range for Enliven Therapeutics Inc.: cautious scenario $27.12, base $36.16, optimistic $45.20 per share (as of Nov 11, 2026, price $47.62). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Enliven Therapeutics Inc. (ELVN)?
Balance-sheet figures for Enliven Therapeutics Inc. (as of Nov 11, 2026): return on equity −16.8%. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is ELVN from its 52-week high?
Enliven Therapeutics Inc. trades at $47.62, about 22% below its 52-week high of $61.15 and 215% above the low of $15.14 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $36.16 is for.
Which stocks are comparable to Enliven Therapeutics Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Enliven Therapeutics Inc. stock attractive at the current price?
The data as of Nov 11, 2026: price $47.62, calculated fair value $36.16 (−24%), Quality Score 32/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Enliven Therapeutics Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Enliven Therapeutics Inc. (ELVN)?
The closing price on Nov 16, 2026 was $47.62. Our estimate is $36.16, about 24% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Enliven Therapeutics Inc. right now?
The price sits above even our optimistic bull case ($45.20). The favourable scenario is already priced in. Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Enliven Therapeutics Inc.
How large is the market capitalisation of Enliven Therapeutics Inc. (ELVN)?
The market capitalisation of Enliven Therapeutics Inc. is $3.5B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Enliven Therapeutics Inc. (ELVN)?
Earnings per share at Enliven Therapeutics Inc. are $−1.76. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Enliven Therapeutics Inc. (ELVN)?
The return on equity (ROE) of Enliven Therapeutics Inc. is −16.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Enliven Therapeutics Inc. (ELVN)?
On an EBIT basis the return on assets of Enliven Therapeutics Inc. is −31.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Enliven Therapeutics Inc. (ELVN) generate?
The free cash flow of Enliven Therapeutics Inc. is −$70.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Enliven Therapeutics Inc. (ELVN) hold?
Enliven Therapeutics Inc. holds more cash than debt, $150M net (balance sheet 30 Sep 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Enliven Therapeutics Inc. in the live analysis
One click puts Enliven Therapeutics Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.